{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:37:08Z","timestamp":1777289828188,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40272-026-00748-3","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T07:02:19Z","timestamp":1774854139000},"page":"325-329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ferric Maltol: Pediatric First Approval"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0121-7645","authenticated-orcid":false,"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"issue":"3","key":"748_CR1","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/bjh.19268","volume":"204","author":"PO Ebea-Ugwuanyi","year":"2024","unstructured":"Ebea-Ugwuanyi PO, Vidyasagar S, Connor JR, et al. Oral iron therapy: current concepts and future prospects for improving efficacy and outcomes. Br J Haematol. 2024;204(3):759\u201373.","journal-title":"Br J Haematol"},{"issue":"5","key":"748_CR2","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1016\/S2352-3026(25)00038-9","volume":"12","author":"AE Benson","year":"2025","unstructured":"Benson AE, Lo JO, Achebe MO, et al. Management of iron deficiency in children, adults, and pregnant individuals: evidence-based and expert consensus recommendations. Lancet Haematol. 2025;12(5):e376\u201388.","journal-title":"Lancet Haematol"},{"key":"748_CR3","unstructured":"Gass D, Freiberg A, Kim JJ, et al. Efficacy and safety of a novel oral iron (ferric maltol) in children and adolescents; a randomized, multicenter, open-label, active comparator study [abstract no. P4.017 plus poster]. In: American Association of Pediatrics (AAP) Conference. 2025."},{"issue":"1","key":"748_CR4","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1182\/hematology.2023000496","volume":"2023","author":"CT Cohen","year":"2023","unstructured":"Cohen CT, Powers JM. Intravenous iron therapy in pediatrics: who should get it and when is the right time? Hematology Am Soc Hematol Educ Program. 2023;2023(1):630\u20135.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"748_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/PG9.0000000000000090","volume":"2","author":"S Allen","year":"2021","unstructured":"Allen S, Auth MK, Kim JJ, et al. Safety, tolerability, and pharmacokinetics of oral ferric maltol in children with iron deficiency: phase 1 study. JPGN Rep. 2021;2(3):e090.","journal-title":"JPGN Rep"},{"key":"748_CR6","unstructured":"Shield Therapeutics plc. FDA approves Feraccru\u00ae with a broad label of treating iron deficiency in adults [media release]. 26 Jul 2019. https:\/\/shieldtherapeutics.com\/."},{"key":"748_CR7","unstructured":"Shield Therapeutics Inc. Ferric maltol: US prescribing information. 2025. https:\/\/www.accrufer.com\/. Accessed 19 Feb 2026."},{"issue":"3","key":"748_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/MIB.0000000000000314","volume":"21","author":"C Gasche","year":"2015","unstructured":"Gasche C, Ahmad T, Tulassay Z, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015;21(3):579\u201388.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"748_CR9","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1053\/j.ajkd.2021.03.020","volume":"78","author":"PE Pergola","year":"2021","unstructured":"Pergola PE, Kopyt NP. Oral ferric maltol for the treatment of iron-deficiency anemia in patients with CKD: a randomized trial and open-label extension. Am J Kidney Dis. 2021;78(6):846-56.e1.","journal-title":"Am J Kidney Dis"},{"key":"748_CR10","unstructured":"European Medicines Agency. Ferric maltol: EU prescribing information. 2023. https:\/\/www.ema.europa.eu\/. Accessed 16 Feb 2026."},{"key":"748_CR11","unstructured":"US Food & Drug Administration. FDA approves first prescription oral medicine for iron deficiency in pediatric patients ages 10 and older [media release]. 22 Dec 2025. https:\/\/www.fda.gov\/."},{"key":"748_CR12","unstructured":"Shield Therapeutics. US FDA approves extension of the indication for ACCRUFeR\u00ae to include children 10 years and older with iron deficiency (ID) [media release]. 22 Dec 2025. https:\/\/shieldtherapeutics.com\/."},{"key":"748_CR13","unstructured":"European Medicines Agency. Start of procedure: Type II variation - extension of indication under evaluation by the CHMP 28 July 2025. 2025. https:\/\/www.ema.europa.eu\/. Accessed 16 Feb 2026."},{"key":"748_CR14","unstructured":"Shield Therapeutics plc. Licence agreement in Japan for ACCRUFeR\u00ae [media release]. 22 Apr 2025. https:\/\/shieldtherapeutics.com\/."},{"key":"748_CR15","unstructured":"Shield Therapeutics plc. Shield Therapeutics and Viatris sign collaborative sales agreement for Accrufer\u00ae in the United States [media release]. 13 Dec 2022. https:\/\/shieldtherapeutics.com\/."},{"key":"748_CR16","unstructured":"Kye Pharmaceuticals Inc. Shield Therapeutics and KYE Pharmaceuticals Inc. announce an exclusive licence agreement for the development and commercialisation of Accrufer\u00ae [media release]. 5 Jan 2022. https:\/\/www.kyepharma.com\/."},{"key":"748_CR17","unstructured":"Shield Therapeutics plc, KOREA PHARMA CO LTD. Licence agreement secured in Republic of Korea for Accrufer\u00ae [media release]. 12 Aug 2021. https:\/\/shieldtherapeutics.com\/."},{"key":"748_CR18","unstructured":"Shield Therapeutics plc. Shield Therapeutics announces exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co. Ltd in China [media release]. 8 Jan 2020. https:\/\/shieldtherapeutics.com\/."},{"key":"748_CR19","unstructured":"Shield Therapeutics plc, Norgine BV. Shield Therapeutics and Norgine B.V. (Norgine) enter into an exclusive licence agreement for the commercialisation of Feraccru\u00ae in Europe, Australia and New Zealand [media release]. 19 Sep 2018. https:\/\/shieldtherapeutics.com\/."},{"key":"748_CR20","unstructured":"Shield Holdings AG. Shield Therapeutics signs agreement with AOP Orphan for ST10-021 [media release]. 1 Nov 2010. https:\/\/www.shieldtherapeutics.com."},{"key":"748_CR21","unstructured":"Shield Therapeutics plc. European Patent Office reaches positive decision on Feraccru\u00ae's process patent [media release]. 14 Mar 2019. https:\/\/shieldtherapeutics.com\/."},{"key":"748_CR22","unstructured":"Shield Therapeutics plc. US FDA grants additional 3 years exclusivity for ACCRUFeR\u00ae [media release]. 9 Feb 2026. https:\/\/shieldtherapeutics.com\/."},{"key":"748_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/nu13072269","author":"A Mahalhal","year":"2021","unstructured":"Mahalhal A, Frau A, Burkitt MD, et al. Oral ferric maltol does not adversely affect the intestinal microbiome of patients or mice, but ferrous sulphate does. Nutrients. 2021. https:\/\/doi.org\/10.3390\/nu13072269.","journal-title":"Nutrients"},{"issue":"Suppl 1","key":"748_CR24","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1182\/blood-2025-1126","volume":"146","author":"A Freiberg","year":"2025","unstructured":"Freiberg A, Gass D, Kim JJ, et al. Pharmacokinetics of ferric maltol oral suspension in children and adolescents (1 month to 17 years); a study of iron and maltol metabolism following single and multiple dosing [abstract no. 102]. Blood. 2025;146(Suppl 1):1126\u20137.","journal-title":"Blood"},{"key":"748_CR25","unstructured":"ClinicalTrials.gov. Evaluate the safety and efficacy of ferric maltol oral suspension vs. ferrous sulfate oral liquid in children and adolescents aged 2 to 17 years with iron-deficiency anaemia, with a single arm study in infants aged 1 month to less than 2 years. 2021. https:\/\/clinicaltrials.gov\/. Accessed 19 Feb 2026."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00748-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00748-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00748-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T10:48:58Z","timestamp":1777286938000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-026-00748-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["748"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00748-3","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}